Powered by efficient fully integrated in-house R&D capabilities, Keymed has established an industry-leading innovation engine to accelerate the development of novel treatments.

Keymed has built a diversified and world-competitive pipeline in the fields of auto-immune diseases and oncology. So far, the Company has over 30 in house-developed Class I novel drugs in the pipeline, 10 of which are in clinical development at different stages. Each of the drug candidates is among the first three domestically developed for its targets/in its class to have obtained IND approval in China and/or the U.S.

To support the continuous improvement of R&D capabilities and the demand for large-scale commercial manufacture, Keymed's high-standard manufacturing campus located in Tianfu International Bio-town, Chengdu is under construction, in a site occupying 75,333 square meters. After completion, it can provide a robust manufacturing capacity over 70,000 liters, which can satisfy commercial production of 5-15 antibodies. The Manufacturing Campus Phase I Project finished construction and started operation by the end of 2022. The Company has a total of 18,600L capacity, with all the facilities are built and designed in compliance with the cGMP requirements of NMPA and FDA.